These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 32014125

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
    Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A.
    Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM, Melchardt T, Greil R.
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
    Gerds AT, Castro C, Snopek F, Flynn MM, Ellis AG, Manning M, Urbanski R.
    J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
    Qin A, Wu D, Li Y, Zhang J, Wang W, Shen W, Liao J, Lin S, Chang C, Chen H, Cui J, Su X.
    Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
    [Abstract] [Full Text] [Related]

  • 8. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
    Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C.
    Ann Hematol; 2024 Jul; 103(7):2299-2310. PubMed ID: 38438627
    [Abstract] [Full Text] [Related]

  • 9. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
    Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA, Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams.
    Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
    [Abstract] [Full Text] [Related]

  • 10. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
    Illés Á, Pinczés LI, Egyed M.
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
    Shimoda K, Qin A, Komatsu N, Kirito K.
    Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Ropeginterferon alfa-2 b for the therapy of polycythemia vera].
    Červinek L.
    Vnitr Lek; 2020 Aug; 66(5):309-313. PubMed ID: 32942868
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K.
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.